MRZM News and Press, Marizyme Inc From 05/03/23

JUPITER, FL - ( NewMediaWire ) - May 03, 2023 - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel. I am pleased to bring you an...

—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role— FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or &#x...

The IPO market's run of small issuers continued this past week with two healthcare micro caps, joined by five SPACs. The pipeline was fairly active with initial filings from three IPOs and two SPACs. Meihua International Medical Technologies downsized and priced at the midpoint to rai...

Medical device maker Marizyme (OTCQB:MRZM) is seeking to uplist its shares to Nasdaq and conduct a public offering of around $15M. The maker of grafting treatments for use in coronary bypass surgery said in a filing that it plans to offer 3M shares in the range of $4 to $6. Underwriters will ...

Jupiter, FL - ( NewMediaWire ) - January 05, 2022 - Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s DuraGraft rel...

JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc . (“ Marizyme ” or the “ Company ”) ( OTCQB:MRZM ), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Log...

JUPITER, FL - ( NewMediaWire ) - December 03, 2021 - Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnose diseases of unmet clinical need announced today that results of the GOAL Study (Vienna Heart ...

Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it h...

The development-stage biotech company, Marizyme (OTCQB:MRZM +12.8%), has named David Barthel as its new chief executive officer. The appointment comes more than seven months after the company disclosed the resignation of former CEO Neil Campbell. Mr. Barthel most recently led Health...

JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc . (“ Marizyme ” or the “ Company ”) ( OTCQB:MRZM ), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In hi...